Alimera Sciences

271 articles with Alimera Sciences

• Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021

  5/27/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.

• Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist

  5/17/2021

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today.

• Alimera Sciences Announces First Quarter 2021 Financial Results

  4/28/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the first quarter of 2021

• Alimera Sciences to Report First Quarter 2021 Financial Results on Wednesday, April 28, 2021 and Provide Corporate UpdateConference Call to be held Thursday, April 29, 2021 at 9:00am Eastern Time

  4/22/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report first quarter 2021 financial results on Wednesday, April 28, 2021 after the market close.

• Alimera Sciences Receives $20 Million From Ocumension Therapeutics

  4/14/2021

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announced today that Ocumension Therapeutics (Ocumension), a company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant

• Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

  4/9/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET

• Alimera Sciences to Participate in Benzinga Biotech Small Cap Conference

  3/18/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announced today that President and CEO Rick Eiswirth will participate in the Benzinga Biotech Small Cap Conference to be held March 24-25, 2021. Mr. Eiswirth will present on March 25 at 12:00 pm ET.

• Alimera Sciences Continues to Execute on Its Expansion Strategy in Denmark and Luxembourg, and Achieves Extended Reimbursement in Ireland

  3/17/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces continued execution on its geographic expansion strategy with publication of ILUVIEN pricing in Denmark and Luxembourg

• Alimera Sciences to Present at Maxim Group’s Inaugural Emerging Growth Virtual Conference

  3/11/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at Maxim Group’s Inaugural Emerging Growth Virtual Conference to be held March 17-18, 2021.

• Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.

• Alimera Sciences Reports Fourth Quarter and 2020 Results

  2/24/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the fourth quarter and full year 2020

• Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications

  2/18/2021

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.

• Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate UpdateConference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time

  2/17/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces today that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021 after the market close. Management will host a conference call at 9:00 AM ET on Thursday, February 25, 2021 to r

• Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference

  2/15/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021.

• Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020

  1/19/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million.

• Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

  1/5/2021

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning at 6:00 AM Eastern Time on Monday, January 11, 2021,

• Alimera Sciences Announces Launch of ILUVIEN® in the NetherlandsILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications

  12/9/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Irish subsidiary, has launched ILUVIEN® in the Netherlands.

• Alimera Sciences to Present at the 13th Annual LD Micro Main Event Virtual Conference

  12/8/2020

  Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that CEO Rick Eiswirth will present a corporate overview at the 13th Annual LD Micro Main Event virtual investor conference on Monday, December 14 at 8:20 AM PST/11:20 AM EST

• Alimera Sciences Announces Participation at the 11th Annual Craig-Hallum Alpha Select Conference on Tuesday, November 17, 2020

  11/16/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that Rick Eiswirth, Alimera’s President and Chief Executive Officer, will participate in the Craig-Hallum Capital Group’s annual Alpha Select Conference on Tuesday November 17, 2020. The conference consists of one-on-one and small group meetings, which will t

• Alimera Sciences Announces Real-World Clinical Data for ILUVIEN® to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference

  11/12/2020

  Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world clinical data for ILUVIEN® will be featured in 3 posters at the American Academy of Ophthalmology 2020 Virtual Conference